Viral features of lamivudine resistant hepatitis B genotypes A and D. - Wikidata - wikimedia - TriplyDB

Viral features of lamivudine resistant hepatitis B genotypes A and D.

Viral features of lamivudine resistant hepatitis B genotypes A and D.

http://www.wikidata.org/entity/Q44749272

about

Treatment strategies according to genotype for chronic hepatitis B in children Diagnosis of viral hepatitis.Virologic response at 12 months of treatment predicts sustained antiviral efficacy in patients with adefovir-treated Lamivudine-resistant chronic hepatitis B Hepatitis B virus genotyping among chronic hepatitis B individuals with resistance to Lamivudine in shahrekord, iran.Hepatitis B virus (HBV) subgenotypes C2 and B2 differ in lamivudine- and adefovir-resistance-associated mutational patterns in HBV-infected Chinese patients.Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2).European multicenter evaluation of high-density DNA probe arrays for detection of hepatitis B virus resistance mutations and identification of genotypes Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D Resistance to lamivudine therapy: is there more than meets the eye?Molecular virology in chronic hepatitis B: genotypes.Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.Doubly Spliced RNA of Hepatitis B Virus Suppresses Viral Transcription via TATA-Binding Protein and Induces Stress Granule Assembly.Therapeutic implications of hepatitis B virus genotypes.Antiviral therapies: focus on hepatitis B reverse transcriptase Future prospectives for the management of chronic hepatitis B.Molecular testing in the diagnosis and management of chronic hepatitis B Role of viral factors in the natural course and therapy of chronic hepatitis B.Hepatitis B virus genotypes: natural history and implications for treatment.Management of antiviral drug resistance in chronic hepatitis B Prevalence of HBV genotypes among Egyptian hepatitis patients.Mutations associated with drug resistance and prevalence of vaccine escape mutations in patients with chronic hepatitis B infection.Prevalence, incidence, and clinical relevance of the reverse transcriptase V207I mutation outside the YMDD motif of the hepatitis B virus polymerase during lamivudine therapy.Hepatitis B virus genotyping among chronic hepatitis B patients with resistance to treatment with lamivudine in the City of Ribeirão Preto, State of São Paulo.Distribution and characteristics of hepatitis B virus genotype C subgenotypes in China.Detection of rtN236T mutation associated with adefovir dipivoxil resistance in Hepatitis B infected patients with YMDD mutations in Tehran.Hepatitis B virus genotypes in Europe.Genotyping of hepatitis B virus in a cohort of patients evaluated in a hospital of Porto Alegre, South of Brazil.Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern.Correlation of hepatitis B virus (HBV) genotypes and mutations in basal core promoter/precore with clinical features of chronic HBV infection.Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion.Polymerase domain B mutation is associated with hepatitis relapse during long-term lamivudine therapy for chronic hepatitis B.Evolution of drug-resistant mutations in HBV genomes in patients with treatment failure during the past seven years (2010-2016).Factors influencing inadequate or suboptimal response to adefovir with or without genotypic resistance

P2860

Q28066476-D904B03C-3F15-461B-A7A3-C3117861476A Q33557877-7363D43C-E605-4863-ABE3-872FB0D37F87 Q33918275-42FD818B-57B9-4C13-86F8-900F902550D1 Q34068574-BD71066A-39C3-45CE-BCC2-EF951F4930A8 Q34433062-9444D452-8CB5-4930-8432-634F5C93008C Q34700034-DC641378-7A66-4C52-9621-605909CF0447 Q34719476-A595B76D-55FF-4520-B384-7C4523C33E7F Q35073136-5B4E0F94-E4B9-489F-A884-2DAD93FFD713 Q35597612-42E4B04B-282C-46AF-A789-46E6C36E52A1 Q35980473-C7108FB2-AF43-4813-878E-FAF45D52B1E9 Q36027130-22911CE9-8E1F-484F-B4B8-3265CBBF6E25 Q36177722-DE5EE3BC-4C4D-4556-B2DF-BB1628F9D75D Q36281882-3C0FE404-4821-4373-8CDB-D9567479F187 Q36338675-1C899DC8-662B-447F-B154-D8460226D57A Q36467514-4D825AF2-AE58-4FF0-956E-26EF3316572B Q36841719-E21A7AFD-DC71-45F8-ABBC-A7401C601909 Q36881140-18F96C42-A4B1-48EE-A894-70098E401AF3 Q37280144-0D5AB577-6FB5-4ABD-94BA-83B75E555D6E Q37346012-9FF10EB6-035A-4BA9-B86D-AA8696B84AAF Q38247981-B2310CBA-0ACE-4B77-BE7F-F67D2B400F5F Q39131034-984C8F2C-C335-43D7-BDF4-A91B6A364651 Q40202952-ED231041-3EF2-4F3F-AD84-18309AC93240 Q41844014-1DF1857C-4B6D-4B67-9E51-7BCC740350B3 Q43012086-B81C468C-2F5D-4829-B821-DCE96E9A0295 Q43037749-5A81F3CA-2480-4694-B4C9-F2F2E235418A Q43243611-92BD2BAC-203F-4B0E-A115-FB9B94167E44 Q45275480-E37CA485-1A35-4C7A-839C-9F811B3DF5AF Q45375563-DDB2589F-B090-406D-946E-2E7DB957F9AC Q45377033-2219BFB2-AC24-4237-81EC-57C3F17B1203 Q45407035-5EEC8834-78C6-44F0-AD7D-52ECBA7376C3 Q46604911-CF22AAB8-8E23-4F58-9F11-2AD368C462EF Q46604917-A528DA0D-3B71-4F5A-A4C1-AC9ABA0DEF2A Q47585685-641EAAD9-C5D8-4754-83D0-21631D4A1C87 Q56895288-0AD326E2-623F-45DE-B6B4-D5B28A2A8836

P2860

Viral features of lamivudine resistant hepatitis B genotypes A and D.

http://www.wikidata.org/entity/Q44749272

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Viral features of lamivudine resistant hepatitis B genotypes A and D.

@en

Viral features of lamivudine resistant hepatitis B genotypes A and D.

@nl

type

label

Viral features of lamivudine resistant hepatitis B genotypes A and D.

@en

Viral features of lamivudine resistant hepatitis B genotypes A and D.

@nl

prefLabel

Viral features of lamivudine resistant hepatitis B genotypes A and D.

@en

Viral features of lamivudine resistant hepatitis B genotypes A and D.

@nl

P1433

Q44749272-41C7D7CC-96E4-49E3-B497-A90B799F82E9

P1476

Q44749272-52BD7FD1-0D3A-4623-A8EC-9D85CE8D8D93

P2093

Q44749272-2EAB1EB0-8B51-471D-93FB-21A68607D4A9

Q44749272-3165D720-EF85-4F59-A0E2-E05C96600A95

Q44749272-7F8CFFCB-A4E2-49E8-B4E2-C5795430EF21

Q44749272-9AA67E09-8001-4195-8EB3-A3CC0CE9CE50

Q44749272-A29F52CF-2C0A-4F94-B54C-2CC565C92C82

Q44749272-AB6BC740-2F2E-4A62-9540-DB82653AB137

Q44749272-ADA2C35A-DCD4-4E68-A827-950AD56F93A3

Q44749272-E87E6426-7450-4D19-B8E6-4666206E6154

Q44749272-F69D83FB-2D93-45E7-9598-9E5571614506

P2860

Q44749272-1290D840-70E4-4AA0-9508-6D10C08CA4F3

Q44749272-146788C1-B8BB-4677-9B85-695F54015440

Q44749272-162C5AFF-F971-4DE9-8EEA-A37356442CAC

Q44749272-19E489CB-126D-469C-9F0D-0FD31B54D239

Q44749272-21A61EB5-8CBE-4339-BA17-BDD962D6ACB2

Q44749272-36C5859B-8C9C-4423-AF0B-C5FEEB818973

Q44749272-48436787-D04D-4ACA-9464-E42E530F805F

Q44749272-4992DE1D-D396-4E4C-9689-A5B1B205F6D6

Q44749272-508AEB78-F8BA-4D5E-9FED-D1EF5BBB660B

Q44749272-52FB8E40-8421-4984-81E0-00591D631F42

P304

Q44749272-6EEFF5A4-C33B-4716-9CB9-10E0A43B030B

P31

Q44749272-A8D2D9D7-FCE5-4B83-9CF9-D3198248F164

P356

Q44749272-DD8D7F02-858D-4BFB-986E-3C907198D42A

P407

Q44749272-82243703-8F85-4D4A-BB1A-59A7E60F74AE

P433

Q44749272-176D8AE5-A1C0-49AC-86FF-F047C38951FA

P478

Q44749272-CB9A177D-9DBD-49DF-84EA-0BFD4B2B8D3A

P50

Q44749272-911875F8-72A4-4592-B9F5-AA80202D178F

P577

Q44749272-BF50D538-C7C0-4A00-8402-DFEF0D5606CF

P698

Q44749272-02676FEF-346D-4436-BB8F-D8B21DDB5307

P356

P1433

P1476

Viral features of lamivudine resistant hepatitis B genotypes A and D.

@en

P2093

Bernhard Zöllner

http://www.w3.org/2001/XMLSchema#string

Elisabeth Puchhammer-Stöckl

http://www.w3.org/2001/XMLSchema#string

Heinz-Hubert Feucht

http://www.w3.org/2001/XMLSchema#string

Josef Kletzmayr

http://www.w3.org/2001/XMLSchema#string

Jörg Petersen

http://www.w3.org/2001/XMLSchema#string

Lutz Fischer

http://www.w3.org/2001/XMLSchema#string

Martina Sterneck

http://www.w3.org/2001/XMLSchema#string

Matthias Schröter

http://www.w3.org/2001/XMLSchema#string

Rainer Laufs

http://www.w3.org/2001/XMLSchema#string

P2860

MEGA2: molecular evolutionary genetics analysis software

Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region.

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial.

Discontinuous epitopes of hepatitis B surface antigen derived from a filamentous phage peptide library.

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective.

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw.

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation.

Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy.

P304

42-50

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.20016

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

39

http://www.w3.org/2001/XMLSchema#string

P50

Elisabeth Puchhammer-Stöckl

P577

2004-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14752821

http://www.w3.org/2001/XMLSchema#string